are glp-1 agonists safe For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Medications: Everything You Need
Description
C., Allen, S., Sarker, E., Wu, Q., Stefanski, A., Jouravskaya, I., & ATTAIN-2 Trial Investigators (2026)
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y
Available from: U.S
(d) full stomach precautions to be taken if GLP-1RAs were not held as suggested before elective procedures [20]
doi: 10.1039/C9BM01426H
Revolutionizing GLP-1 delivery with sublingual administration Recently, a new sublingual modality for GLP-1 receptor agonists (and also for insulins) delivery has been developed by the Dutch company SUBLIN BV, established in 2018 as a spin-out of the healthcare branch of NanoServe BV
